Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

Swiss drugmaker Novartis' oral multiple sclerosis (MS) drug remibrutinib meaningfully reduced relapses in patients, according to data presented ​at a medical conference in Toronto on Friday, but less than ‌analysts had expected.